More than 35 per cent of the medical research in Norwegian medical centres is performed at Rikshospitalet–Radiumhospitalet. This is the result of the hospital’s general research strategy and its extensive international and national network cooperation.

In this way, the medical centre complies with the requirements of its owner and patients relating to its role as national reference hospital, responsible for introducing and developing new medical examination methods, treatment methods and follow-ups. Research that supports prioritised areas of commitment will also safeguard the operation and development of national and multi-regional assignments, as well as the functions of the medical resource centres.

G. Gaudernack

The institute seminar on Wednesday March 10th is given by Gustav Gaudernack from the Department of Immunology. Title of his talk:
Cancer immunotherapy: From bench to bedside and from mutant ras to cancer stem cells

The seminar takes place in the Auditorium (New Research Building Montebello) and starts at 10:30.

A. Sagona

PhD student Antonia Sagona and her co-workers in Harald Stenmark´s group at the Centre for Cancer Biomedicine, Institute for Cancer Research, have uncovered a new functional mechanism for a known tumour suppressor, the class III phosphatidylinositol 3-kinase (PI3K-III), a protein complex that mediates formation of the membrane lipid, phosphatidylinositol 3-phosphate (PtdIns3P). The findings are published as a main article in the April 2010 issue (advance online publication 7 March 2010) of Nature Cell Biology (impact factor 17.774) .

From left: H.R. Brekke, F. Ribeiro and M. Kolberg.

The "Molecular Genetics group" at the Department of Cancer Prevention, headed by Ragnhild A. Lothe, has recently published a translational research paper in the highly rated "Journal of Clinical Oncology" (journal impact factor 17.2). The article - entitled "Genomic Changes in Chromosomes 10, 16, and X in Malignant Peripheral Nerve Sheath Tumors Identify a High-Risk Patient Group" is published in the "Translational oncology" section.
The first three authors are PhD candidate Helge R. Brekke (1st author), dr. Franclim Ribeiro and dr. Matthias Kolberg.